News | May 10, 2016

Imricor Enrolls First Patients in Study of Vision-MR Ablation Catheter

Study of 35 patients will evaluate device for treatment of atrial flutter under real-time MRI guidance

Imricor, Vision-MR ablation catheter, clinical study, MRI guidance

May 10, 2016 — Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance. The study is sponsored by the Leipzig Heart Center in Leipzig, Germany. Professor Gerhard Hindricks M.D., head of the Department of Electrophysiology at the heart center, is the principal investigator. This single-center study will enroll up to 35 patients.

"We truly believe that ablating in the MRI adds substantial benefits to our standard procedures," said Hindricks. "For example, during one procedure, we were able to visualize with MR an abnormality in the patient's heart and modify our catheter placement to successfully complete the ablation. In a traditional lab, this would have been a 'difficult' procedure and we would not have known why, but with MR, we were able to see the anatomical challenges and tailor the ablation. This is quite exciting."

Imricor's Vision-MR catheter, when used with the Advantage-MR EP Recorder/Stimulator System, allows physicians to perform cardiac ablations under MRI guidance. With real-time MRI, physicians can individualize the ablation for each patient's unique cardiac structure and substrate. In addition, they can assess lesion quality and fill gaps in ablation lines during the initial procedure. Ablations guided by MRI have the potential to improve outcomes and provide safer, more cost-effective treatment – all in an environment that is free of radiation for both the patient and physician.

For more information: www.imricor.com


Related Content

News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
Subscribe Now